- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00701207
Study of Nicotine Patches in Patients With Sarcoidosis
November 1, 2021 updated by: Elliott Crouser MD
Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors
The purpose of this study is to compare peoples with disease (sarcoidosis) to those without disease. We want to see if people with sarcoidosis have a different immune response to those people without disease.
The goal of this study is to see if the nicotine patch is an anti-inflammatory treatment for sarcoidosis.
Study Overview
Detailed Description
Until recently, there was no good explanation for the fact that smoking cigarettes actually reduces the risk of sarcoidosis.
Research studies have shown that the nicotine, a common component of cigarette smoke, strongly suppresses the immune system and reduces the type of inflammation that is characteristic of sarcoidosis in the lungs.
We propose that nicotine treatment, administered in the form of a skin patch, will reduce the severity of lung disease in patients with sarcoidosis.
Sarcoidosis patients who volunteer to participate in this study will submit standardized questionnaires relating to their quality of life and the severity of their shortness of breath before and after treatment.
We will also compare objective measures of lung function, radiographic parameters, and the severity of lung inflammation.
We predict that nicotine treatment will reduce the severity of sarcoidosis symptoms, improve lung function, and resolve lung inflammation.
If our hypothesis is proven to be correct in this relatively small group of patients, we will perform additional studies in a larger group of patients and will consider the features of sarcoidosis patients that predict a favorable response to nicotine and other nicotine-like drugs.
If nicotine is ultimately found to be an effective treatment for sarcoidosis, it may replace some of the existing treatments which are frequently ineffective and have unacceptable side-effects.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- • Symptomatic (active) granulomatous lung disease (radiographic stage II or III disease) at least 6 months after the diagnosis. This selects patients that have the chronically active variant of sarcoidosis and will likely require long-term treatment (33).
Exclusion Criteria:
• Active smokers,
- Previous splenectomy,
- Those requiring high-dose immunosuppression [i.e., ≥ 0.2 mg/kg/day prednisone (or equivalent) or > 10 mg/week methotrexate or requires second line cytolytic agents (e.g., cyclophosphamide, azathioprine) or anti-TNF treatments (e.g., thalidomide, anti-TNF antibodies, etc.)] to control disease activity.
- We will also exclude patients at high risk of complications relating to the use of nicotine. This will include patients with a known intolerance of nicotine or those with active cardiac or central nervous system disease who are at higher risk of cardiac arrhythmias or seizures.
- We will also exclude patients with extensive pulmonary fibrosis based upon lung biopsy or high resolution CT scan criterion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: 2.
control group-no intervention
|
|
No Intervention: 3
Healthy control group-blood and sputum samples
|
|
Experimental: 1.
nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
|
daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine if nicotine treatment reduces lung inflammation.
Time Frame: 3 months
|
Normalization of immune response
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine if expression of α7 nAChR on monocytes/macrophages derived from the blood/lungs correlates with the severity of pulmonary sarcoidosis.
Time Frame: 3 months
|
Improvement in FVC
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Elliott D. Crouser, M.D., Ohio State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2008
Primary Completion (Actual)
December 31, 2010
Study Completion (Actual)
December 31, 2010
Study Registration Dates
First Submitted
June 17, 2008
First Submitted That Met QC Criteria
June 18, 2008
First Posted (Estimate)
June 19, 2008
Study Record Updates
Last Update Posted (Actual)
November 8, 2021
Last Update Submitted That Met QC Criteria
November 1, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Lung Diseases
- Lung Diseases, Interstitial
- Sarcoidosis, Pulmonary
- Sarcoidosis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- 2008H0006
- S-07-006 (Other Grant/Funding Number: American Thoracic Society)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Sarcoidosis
-
Celularity IncorporatedTerminatedStage 2 Pulmonary Sarcoidosis | Stage 3 Pulmonary SarcoidosisUnited States
-
University Hospital, LilleTerminated
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedSarcoidosis; Antimycobacterial TherapyUnited States
-
National Jewish HealthAmerican Thoracic SocietyCompletedPulmonary SarcoidosisUnited States
-
Medical University of South CarolinaHoffmann-La RocheTerminated
-
University of Milano BicoccaAgenzia Italiana del FarmacoCompletedPulmonary SarcoidosisItaly
-
Daniel DobererTerminatedPulmonary Hypertension | SarcoidosisAustria
-
Ohio State UniversityThe Cleveland ClinicCompletedSarcoidosisUnited States
-
Ohio State UniversityTerminated
Clinical Trials on nicotine patch
-
McNeil ABCompleted
-
Vanderbilt University Medical CenterCompletedDown Syndrome | Mild Cognitive ImpairmentUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedTobacco Use DisorderUnited States
-
National Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Tobacco Use Disorder | Schizophrenia and Disorders With Psychotic FeaturesUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedNicotine DependenceUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBreast Cancer | Colorectal Cancer | Tobacco Use Disorder | Lung Cancer | Prostate CancerUnited States
-
McNeil ABCompleted
-
Massachusetts General HospitalStanley Medical Research Institute; North Suffolk Mental Health AssociationCompleted